CNBC's Faber: Bausch & Lomb Likely to Stay With Warburg Offer
Bausch & Lomb is likely to stick to its agreement to be acquired by Warburg Pincus for $3.67 billion, or $65 per share in cash, reported CNBC's David Faber.
A Bausch & Lomb special committee, comprised of independent directors of the optical-care company, is meeting Monday to review Warburg's acquisition -- and a competing, unsolicited bid from Advanced Medical Optics for $75 per share.
The Advanced Medical Optics offer would break down into $45 per share in cash and $30 in Advanced Medical Optics stock.
"Based on communications between the two companies, it seems as though they [Bausch & Lomb] will reverse themselves" and fall back on the Warburg Pincus offer, Faber said.
"According to people familiar with the situation, they don't believe that AMO's deal is reasonably likely to be consummated -- because of AMO shareholders and the potential that they will vote against it," Faber reported.
The entire Bausch & Lomb board is slated to meet Tuesday to consider the two offers, and whether to continue talks with Advanced Medical Optics, whose offer was unsolicited.
Bausch & Lomb shares lost $1.31, or 1.94%, at $66.19 in Monday early-afternoon trading on the New York Stock Exchange.